BAIT 628
Alternative Names: BAIT-628Latest Information Update: 16 Jan 2024
At a glance
- Originator Astante Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Nov 2023 Preclinical trials in Cancer in USA (unspecified route) before November 2023 (Astante Therapeutics pipeline, November 2023)